An open label, randomized phase 3 clincal trial of Nivolumab vs therapy of investigator's choice in recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
March 1, 2014
End Date
February 28, 2022
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
March 1, 2014
End Date
February 28, 2022